Optiscan’s MedTech platform also offers exciting potential in the lucrative equine veterinary care market, with its real-time, non-invasive imaging technology able to improve not only surgical precision but also diagnostic accuracy.

Optiscan Imaging CEO and managing director Dr Camile Farah said: “It marks another significant milestone in our efforts to demonstrate that the medical benefits derived from Optiscan’s technology platform extend beyond the treatment of humans. By providing real-time, high-resolution imaging solutions, we aim to empower veterinarians to make quicker, more accurate diagnoses, particularly in critical areas like oncology.”

Optiscan says its move into the veterinary sector could also yield further opportunities such as reproductive assistance in cattle, sheep and pigs – an idea originally cited by Optiscan’s biggest shareholder, Bob Peters – a prominent West Australian businessman and horse racing identity.

After revealing its landmark “InVue” imaging device for microscopic precision surgery earlier in the year and a collaboration with the well-regarded Mayo Clinic to develop its technology for robotic surgery, Optiscan shares have settled around the 16.5c mark, up almost 70 per cent since June.

With the company now entering the addressable market for companion animals, one which could eventually even challenge the human market for size, it may just be on the cusp of delivering something particularly special for both people and their pets.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au